CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Total revenue		$ 468	$ 15,018
Operating expenses
Research and development		9,814	10,701
General and administrative		12,138	3,663
Total operating expenses		21,952	14,364
(Loss)/income from operations		(21,484)	654
Other income/(expense):
Interest income		1,588	83
Interest expense			(74)
Research and development incentives		1,157	1,048
Total other income/(expense)		2,745	1,057
(Loss)/profit before income tax		(18,739)	1,711
Tax benefit		516	863
Net (loss)/income		(18,223)	2,574
Net loss attributable to noncontrolling interest		43	22
Net (loss)/income attributable to Vaccitech plc shareholders		$ (18,180)	$ 2,596
Weighted-average ordinary shares outstanding, basic		38,013,399	37,191,022
Weighted-average ordinary shares outstanding, diluted		38,013,399	38,346,668
Net (loss)/income per share attributable to ordinary shareholders, basic		$ (0.48)	$ 0.070
Net (loss)/income per share attributable to ordinary shareholders, diluted		$ (0.48)	$ 0.068
Net Income / (loss)		$ (18,223)	$ 2,574
Other comprehensive gain/(loss) - foreign currency translation adjustments		4,580	(5,983)
Comprehensive loss		(13,643)	(3,409)
Comprehensive loss attributable to noncontrolling interest		37	37
Comprehensive loss attributable to Vaccitech plc shareholders		(13,606)	(3,372)
License revenue
Total revenue	[1]	$ 468	15,009
Research grants and contracts
Total revenue			$ 9

[1] Includes license revenue from related parties for the three month periods ended March 31, 2023 and 2022, of $0.5 million and $15.0 million, respectively.